The invention relates to medical applications of the HDAC inhibitor resminostat ((E)-3-[1-{4-Dimethylaminomethyl-benzenesulfonyl)-1H-pyrroi-3-yl]-N-hydroxy-acrylamide) or a salt or solvate thereof in the treatment of benign or malignant neoplasia in a human subject, wherein said human subject is an Asian, and wherein said treatment comprises administering resminostat or a salt or solvate thereof to said human subiect in a daily dose of less than 600 mg resminostat, and administering at least one further chemotherapeutic agent to said human subject.